Wake Research Revenue and Competitors
Estimated Revenue & Valuation
- Wake Research's estimated annual revenue is currently $36M per year.
- Wake Research's estimated revenue per employee is $201,000
Employee Data
- Wake Research has 179 Employees.
Wake Research's People
Name | Title | Email/Phone |
---|---|---|
1 | VP, Marketing & Advertising – Patient Engagement Operations | Reveal Email/Phone |
2 | Controller | Reveal Email/Phone |
3 | VP Clinical Affairs | Reveal Email/Phone |
4 | Head Clinical Operations | Reveal Email/Phone |
5 | Controller | Reveal Email/Phone |
6 | Controller | Reveal Email/Phone |
7 | Associate Director Business Development | Reveal Email/Phone |
8 | Regional Director- East | Reveal Email/Phone |
9 | Director, Head Clinical Quality | Reveal Email/Phone |
10 | Director Learning and Development | Reveal Email/Phone |
Wake Research Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.8M | 29 | 4% | N/A | N/A |
#2 | $3.2M | 16 | 0% | N/A | N/A |
#3 | $83.2M | 414 | 7% | N/A | N/A |
#4 | $31M | 154 | 56% | N/A | N/A |
#5 | $66.6M | 265 | 0% | $35M | N/A |
#6 | $10.9M | 54 | 6% | N/A | N/A |
#7 | $6.8M | 34 | -6% | N/A | N/A |
#8 | $165.7M | 216 | 14% | $250.7M | N/A |
#9 | $26.5M | 132 | -11% | $637.8K | N/A |
#10 | $49.4M | 246 | 6% | N/A | N/A |
What Is Wake Research?
Wake Research is an Organization of Unified Investigational Sites working closely with and meeting the needs of the global bio-pharmaceutical, biotechnology, medical device, pharmaceutical industry and clinical research organizations. Wake Research was founded by and continues to be affiliated with a large multi-specialty group practice. Additionally, Wake Research has its own proprietary patient database of more than 2 million potential clinical trial participants—men and women, children and adults, across all ethnicities—for all kinds of adaptive and other types of trial designs. Wake Research Headquarters – Raleigh, NC Wake Research Headquarters is the centralized hub of our organization. The site is home to our business development team, marketing and advertising department, centralized recruiting team and in-house QA/QC department which monitors and enforces our standards and practices. It is also home to Wake Research Associates and Carolina Phase I. Unified Investigational Sites: - Breco Clinical Research - Sugar Land, TX - Carolina's GI Research - Raleigh, NC - Carolina Phase I Clinical Research, Raleigh, NC - Carolina Institute of Clinical Research, Fayetteville, NC - ClinSearch - Chattanooga, TN - Digestive Health Specialists - Dothan, AL - GI Associates and Endoscopy Center, Flowood, MS - Global Medical Research, DeSoto, TX - Medical Center for Clinical Research, San Diego, CA - Medical Research Center of Memphis, Memphis, TN - Metro Atlanta Gastroenterology, Atlanta, GA - Mount Vernon Clinical Research, Atlanta, GA - Pharmacology Research Institute - Los Angeles, CA - Tucson Neuroscience Research, Tucson, AZ We are fully equipped to meet the needs of sponsors and CROs in the conduct of Phase I-IV clinical trials in a large variety of indications. Our Phase I facility (Carolina Phase I Clinical Research) is ideal for inpatient/outpatient studies. Some of our amenities include: semi-private rooms, meal services, volunteer lounge, showers, TV, internet and phone access, as well as convenient access to major medical centers. A Proven Track Record of Credible Clinical Research Conducting studies since 1984, we have a combined subject database of more than 2 million, and we're still growing. As of today, our board-certified physicians have completed more than 7,000 successful clinical trials. Clinical trials at our site are always completed on time and with accuracy; we consistently exceed sponsor expectation for integrity, subject enrollment, human protection and expeditious delivery of accurate evaluable data. Wake Research applies standard operating procedures across our integrated organization of sites. Wake Research is a unique and innovative resource for Phase I through Phase IV clinical trials. Our research sites are known for effectively combining strategic accelerated volunteer recruitment and retention with high-quality clinical research practices. Our approach is uncompromising – each study conducted at our site is carefully planned and executed according to regulations with superior quality. Added Clinical Value: - Direct connection with our key opinion leaders and patients - Expertise in medical science and medicine - Thought leadership in clinical research - Thorough understanding of regulatory requirements - Integrated Standard Operating Procedures (SOPs) across all sites Added Operational Value: - Rapid enrollment through our global reach and strong subject database - In-house QA/QC program - Experienced, clinically oriented company management and leadership - Experienced, research educated and certified clinical research coordinators - Dedicated volunteer recruitment department - Exclusive marketing and advertising outreach - Experienced and certified in more than 30 EDC systems - Fully-integrated CTMS Merge - Dedicated marketing and advertising team - Premier training for research staff provided by recognized industry professionals, through certification process
keywords:N/AN/A
Total Funding
179
Number of Employees
$36M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Wake Research News
Use the N&O | Herald-Sun Voter Guide to research candidates running in Wake elections. By STAFF REPORTS. Updated April 24, 2022 10:47 AM.
HB 604 establishes the Kentucky Center for Cannabis Research at the University of Kentucky to research the efficacy of medical cannabis. The...
Aiming to increase the accuracy and timeliness of drought predictions in the United States, a team of environmental researchers at Wake...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $50.5M | 183 | 13% | N/A |
#2 | $15M | 186 | 12% | N/A |
#3 | $35.8M | 186 | 9% | N/A |
#4 | $30.9M | 187 | 9% | N/A |
#5 | $29M | 188 | 6% | N/A |